Chromosomal Microarray Analysis (CMA) from Quest Diagnostics helps physicians and patients understand the cause and plan for treatment

- Gold standard technology—a technically superior array that evaluates 1,900,000 copy number variation (CNV) markers, and 750,000 single nucleotide polymorphism (SNP) markers.
- One of the fastest turnaround times in the industry—10-14 days.
- Results interpreted and reported by a board-certified geneticist.
- A team of genetic counselors at 1-866-GENE-INFO

Chromosomal Microarray Analysis for Developmental Delay, Intellectual Disability, and Autism Spectrum Disorders

ClariSure® Oligo-SNP Postnatal Chromosomal Microarray Analysis from Quest Diagnostics®

The American College of Medical Genetics (ACMG) recommends CMA testing as a first-line genetic test for the initial postnatal evaluation of individuals with nonsyndromic developmental delay/intellectual disability, autism spectrum disorders, and multiple congenital anomalies.¹

Research shows that early intervention treatment services can greatly improve a child’s development.² Rely on ClariSure® CMA testing from Quest Diagnostics to help guide patient management and make informed treatment decisions.

ClariSure® offers a technically superior array, one of the fastest turnaround times in the market, a team of highly trained expert medical directors that specialize in cytogenic interpretation, and genetic counselors with a direct support line.

In just 10-14 days, ClariSure® tests 1,900,000 CNV markers and 750,000 SNP markers.
The Power of the ClariSure® Oligo-SNP Postnatal Chromosomal Microarray Analysis from Quest Diagnostics

The oligonucleotide-single nucleotide polymorphism (oligo-SNP) array contains over 2.6 million probes and covers regions of known and likely CNVs. It can confirm the diagnosis of suspected disorders associated with known chromosomal syndromes and is especially well-suited for determining the genetic cause of less well-described disorders.

The oligo-SNP format provides extensive information across the genome allowing precise definition of breakpoints and detection of uniparental disomy, copy number neutral regions of homozygosity (ROH), and, in some cases, consanguinity.

Chromosomal Microarray Analysis helps physicians and patients:

- Determine the etiology of development delay, intellectual disability, autism spectrum disorders and multiple congenital anomalies.
- Confirm or exclude the diagnosis of known chromosomal syndromes.
- Further define ambiguities arising from cytogenetic or FISH studies.
- Assist in clinical management and genetic counseling.

**Quest Diagnostics Chromosomal Microarray Analysis**

<table>
<thead>
<tr>
<th>Test Name</th>
<th>Test Code</th>
<th>Specimen Requirements</th>
<th>CPT Code(s)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genomic Alterations, Postnatal, ClariSure® Oligo-SNP Array</td>
<td>16478(X)</td>
<td>10 mL whole blood (sodium heparin, green top tube); 5 mL minimum</td>
<td>81229</td>
</tr>
</tbody>
</table>

* The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

For more information about Postnatal Microarray testing, speak to your Quest Diagnostics sales representative or QuestDiagnostics.com

References